Home|Journals|Articles by Year|Audio Abstracts
 

Original Article

AJVS. 2019; 62(1): 79-88


Bergenin Ameliorates Glutamate-Induced Death of Hippocampal Neuronal Cells through Modulation of the Antioxidant Activity and reducing the redox oxygen Species Creation

Mustafa Shukry, Ahmed Hafez, Emad W. Ghazy, Foad Farrag, Mohamed M.A. Abumandour.




Abstract

Oxytosis is a disproportion between the manufacturing and manifestation of reactive oxygen species and the ability of a biological system to restore the resulting injury. In mouse hippocampal cells, HT22, the neuroprotective impact of Bergenin against glutamate-induced oxidative stress was explored. The findings showed that bergenin protected cells against toxicity caused by glutamate at 10 μM and improved their impact in a dose-dependent way until peak protection at 30 μM was achieved. Pretreatment with bergenin, which was clarified using a Cell viability assay (WST-1Assay), considerably suppressed the elevation of glutamate-induced reactive oxygen species and consequently secure HT22 cells against death from glutamate. And this protection reduced by glutamate through restoration of glutathione concentrations. Besides upregulating glutathione activity, the antioxidant ability to scavenge ROS also activates PPARπ, which controls various pro-inflammatory cytokines.

Key words: Bergenin; HT22;Antioxidant activity; ROS; PPARπ agonist






Full-text options


Share this Article


Online Article Submission
• ejmanager.com




ejPort - eJManager.com
Refer & Earn
JournalList
About BiblioMed
License Information
Terms & Conditions
Privacy Policy
Contact Us

The articles in Bibliomed are open access articles licensed under Creative Commons Attribution 4.0 International License (CC BY), which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.